The treatment of advanced cystadenocarcinoma of the ovary with gestronol and continuous oral cyclophosphamide.
Fifty-four patients with advanced cystadenocarcinoma of the ovary were treated with gestronol (Depostat), 200 mg/week, by intramuscular injection and continuous oral cyclophosphamide, the dose of the latter being varied to maintain the patient's white cell count at about 1.5 x 10(9)/l. A combined partial and complete remission rate of 76 per cent was obtained. The length of survival depended upon the type of remission and the type of remission was markedly affected by the amount of tumour removed at initial laparotomy.
D003520:Cyclophosphamide / Q000627:therapeutic use*; D003536:Cystadenocarcinoma / Q000188:drug therapy* / Q000401:mortality; D004359:Drug Therapy, Combination; D005260:Female; D005866:Gestonorone Caproate / Q000627:therapeutic use*; D006801:Humans; D007958:Leukocyte Count; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality
D003520:Cyclophosphamide; D005866:Gestonorone Caproate